

# KING & SPALDING

1730 PENNSYLVANIA AVENUE, N.W.

WASHINGTON, D.C. 20006-4706

TELEPHONE: 202/737-0500

FACSIMILE: 202/626-3737

9 2 0 4 '99 OCT 12 AM 10:09

DIRECT DIAL:

(202) 626-2910

October 6, 1999

Dr. Solomon Sobel, Director  
Division of Metabolism and Endocrine Drug Products  
Center for Drug Evaluation and Research (HFD-510)  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

Ms. Jennie C. Butler, Director  
Dockets Management Branch  
5630 Fishers lane, Room 1061  
Rockville, MD 20857


RE: Docket No. 97N-0314

Dear Dr. Sobel and Ms. Butler:

On April 17, 1998, on behalf of Jones Medical Industries, I sent to Dr. Sobel and subsequently submitted to the relevant docket a letter regarding Levothyroxine which, in a footnote, stated that JMI's internal testing of Jerome Stevens levothyroxine showed that the product did not maintain stability through the expiry period recorded on the label.

Jerome Stevens has provided me with ambient stability data on the lot of product tested by JMI showing that it does retain potency. Hence the statement in footnote 1 in my letter was not accurate.

Sincerely yours,




Jess H. Stribling

97N-0314

C2

**KING & SPALDING**

1730 PENNSYLVANIA AVENUE, N.W.  
WASHINGTON, D.C. 20006-4706



Ms. Jennie C. Butler, Director  
Dockets Management Branch  
5630 Fishers lane, Room 1061  
Rockville, MD 20857

